Sunday, April 22, 4:45-5:05 PM
The Judith J. Saklad Memorial Award celebrates the life and work of the late Judith J. Saklad. Dr. Saklad was a Clinical Pharmacologist and Clinical Coordinator of Pharmaceutical Services at San Antonio State School and Clinical Assistant Professor of Pharmacy and Pharmacology at The University of Texas at Austin and the University of Texas Health Science Center at San Antonio. This award is presented annually to a senior psychiatric pharmacy practitioner who has achieved a level of professional distinction and demonstrates a continuing dedication to the practice of psychiatric pharmacy. CPNP is pleased to announce the recipient of the 2018 Judith J. Saklad Memorial Award, Matthew A. Fuller, PharmD, BCPP, FASHP Clinical Pharmacy Specialist, Psychiatry, Louis Stokes Cleveland VAMC, Cleveland, OH. Dr. Fuller will accept his award during CPNP's Forum on Our Future.
Sunday, April 22, 4:45-6:15 PM
Participate in discussions with the CPNP Board of Directors on issues critical to the profession and CPNP as an organization. The Board will update attendees on the highest priority issues and activities within the association while also providing the opportunity for participant questions and input.
Sunday, April 22, 6:15-7:15 PM
Enjoy engaging with your colleagues as you help kick off CPNP 2018! Heavy hors d'oeuvres and one drink ticket will be provided.
Monday, April 23, 7:00-8:00 AM
This VA Forum will provide an opportunity for VA pharmacists practicing in the area of psychiatric and neurologic pharmacy to collaborate and discuss issues pertinent to VA pharmacy practice. The session will consist of a variety of discussion topics that the facilitators have solicited from VA pharmacists using the VA psychiatric pharmacist listserv. Topics include, but are not limited to: updates from the VA CPPO MH SME group, updates on utilization of MH pharmacists within the ORH CPPO project- CVT, e-consults, etc., discussion on how VA pharmacists are reaching/providing services to our rural Veterans, discussion on whether pharmacists are assisting with meeting the SUD16 metric, updates on formulary issues and concerns as well as Academic Detailing initiatives, MH RPD group update, as well as time for open discussion to discuss VA issues pertinent to mental health.
Monday, April 23 and Tuesday, April 24
Research and networking with colleagues take center stage on Monday and Tuesday when 240+ research and practice posters are displayed. Be sure to stop by both days and take advantage of the three hours of uninterrupted viewing time with poster authors to further explore presented research, innovative practices, and case management. Award finalists will provide platform presentations during Monday's concurrent track with winners announced Monday evening.
Attendees will have extensive opportunities for peer-to-peer idea exchange at CPNP 2018. Hosted and led by CPNP Community and/or CPNP leaders, discussion dens will take place on Sunday, Monday, and Tuesday during the annual meeting, allowing for participation in multiple dens.
Sunday, 4/22 (7:15-8:15 PM)
The Psychiatry Resident Community will host a small group discussion for residents to share lessons learned during their residencies to better prepare individuals as they transition to new practitioners.
Monday, 4/23 (7:00-8:00 AM)
Anti-N-methyl-D-aspartate receptor encephalitis (NMDARE) is an autoimmune disorder that attacks NMDA receptors causing neuropsychiatric symptoms, seizures, movement disorders and cognitive impairment.1 The condition can be treated with intravenous immunoglobulin, corticosteroids or rituximab.2 The initial clinical picture is often complicated, as the neuropsychiatric symptoms may include hallucinations, paranoia, aggression, depression, mania, or grandiosity.2,3 Female patients may also have a teratoma which should be removed as part of treatment. Patients may initially be evaluated by psychiatrists, and antipsychotic medication will be started with a lack of response.3 Misdiagnosis of schizophrenia or bipolar disorder may lead to lack of proper treatment which could lead to death as the condition continues. As the syndrome progresses, autonomic instability is the primary cause of death in patients with NMDARE.3 A case study published in 2007, was one of the first to describe NMDARE in a patient with a teratoma.4
Monday, 4/23 (10:45-11:45 AM)
Stigma is a public health concern that leads people to avoid living, socializing, employing, or working with individuals with mental illness. Researchers have suggested that stigma also exists among health care professionals, including pharmacists independent of how knowledgeable they are about treatments for mental illnesses. Pharmacists may have more stigmatizing views and a higher level of discomfort in interacting with people with mental illness than those with a cardiovascular disease. This may lead to patients avoiding treatment and not receiving the support and care they need to recover. Mental health professionals, including pharmacists, have a crucial role in improving patient health outcomes by increasing mental health literacy and reducing stigma. Through this interactive discussion den, we will briefly provide information to inspire thinking about recognizing forms of stigma, including internal stigma, and its impact on patients. Participants will work in small groups to brainstorm ideas and approaches to create a stigma-free culture and reduce stigmatizing language and behaviors in their community, workplace, and pharmacy schools. Small group ideas will be then be shared with the larger group to foster further discussion. The goal is for participants to learn strategies and best practices from others to improve stigma and promote a supportive culture.
Monday, 4/23 (1:30-2:30 PM)
With the current opioid epidemic the US is facing, it is vital to help patients receive effective treatment for opioid use disorder to help save and extend-lives. Buprenorphine and extended-release naltrexone are widely available treatment options. Comparative efficacy trials of buprenorphine versus extended-release naltrexone have recently been published. Although naltrexone is an option for treatment of opioid use disorder, a barrier to inpatient initiation of naltrexone after detox has been needed for the opioid-free period before initiation. The aim of this session will include sharing of best practices amongst CPNP members around key topics surrounding the use of buprenorphine versus extended-release naltrexone, including discussion of the application of the findings from the comparative studies to current practice, sharing of patient-specific characteristics in treatment selection and different naltrexone initiation strategies.
Monday, 4/23 (2:45-3:45 PM)
The goals of this session are to discuss techniques and strategies for conducting more effective medication groups in both the inpatient and outpatient settings, to explain the importance of patient medication education group documentation and how to complete this task in any practice setting, and to consider ways to link outcome tracking with documentation. Dr. Williams will briefly discuss the logistics of his eight different PMEGs, and how he has improved the quality of his groups over time. Dr. Crouse will then discuss documentation and how this task can be linked to practice outcomes.
Tuesday, 4/24 (7:15-8:15 AM)
The RPD community will meet and discuss the hot topics currently on going in PGY2 Psychiatric Pharmacy. This will include but not be limited to: update on recruitment and status report on the match, review of first year with the new competencies, goals and objectives and how to address/get residents the help needed when they face a personal mental health crisis.
Tuesday, 4/24 (1:30-2:30 PM)
This session will follow-up on topics discussed during 2017-18 teaching community webinars and in the 2017 Teaching Community discussion den. The layered learning model will be discussed as a way to enhance quality IPPEs and APPEs in psychiatry and neurology. Resident teaching roles will be discussed. Residency program directors and preceptors will have the opportunity to share ideas for enhancing resident teaching and documenting resident teaching in PharmAcademic. Ideas for incorporating knowledge and skills in psychiatry and neurology as part of entrustable professional activities will be shared.
Tuesday, 4/24 (2:45-3:45 PM)
While many of us know that psychiatric pharmacists are ideally positioned to support individuals with mental illness across the continuum of care, the role of psychiatric pharmacists has traditionally been associated with inpatient hospital settings. However, as the healthcare environment continues to change and with the majority of mental disorders being treated in primary care, there is a growing need to integrate psychiatric pharmacy services into such settings. Not only would this improve access to mental health services, but it would also allow psychiatric pharmacists to expand their expertise to the management of a variety of primary care conditions. Participants will engage in guided discussions regarding the current state of mental services in ambulatory care, steps needed to implement psychiatric pharmacy services into primary care settings, strategies for demonstrating value, and methods of supporting program sustainability. Residents and new practitioners are welcome!
Wednesday, April 25
Join CPNP Foundation in the tenth annual 5K run/walk bright and early on Wednesday morning. Your donation supports the StigmaFree efforts of both NAMI and the CPNP Foundation equally, and a portion is matched by CPNP. Run, walk or bypass the walk and sleep in, but donate any amount to this wonderful event benefiting NAMI and CPNP Foundation. A t-shirt will be provided to the first 300 participants who register for the event and attend the CPNP Annual Meeting.
While attending CPNP 2018 enjoy complimentary wifi in guest rooms at the host hotel and throughout the meeting spaces.
*=No ACPE credit provided